Basic Information
Ilumetri
Regulatory Information
EMEA/H/C/004514
Authorised
September 17, 2018
July 25, 2018
13
October 2, 2024
Company Information
Spain
Ronda General Mitre 151 08022 Barcelona
ALMIRALL SA
Active Substances Detail
EMA Resources
Detailed Information
Therapeutic Indication
### Therapeutic indication Ilumetri is indicated for the treatment of adults with moderate to severe plaque psoriasis who are candidates for systemic therapy.
Overview Summary
Ilumetri is a medicine that acts on the immune system and is used to treat plaque psoriasis, a disease causing red, scaly patches on the skin. It is used in adults with moderate to severe disease for whom treatments applied to the skin are not suitable. Ilumetri contains the active substance tildrakizumab.